Clinical Trial Detail

NCT ID NCT03520231
Title Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Carboplatin + Cisplatin + Denosumab + Gemcitabine

Carboplatin + Cisplatin + Gemcitabine

Age Groups: adult senior

No variant requirements are available.